MedlinePlus a604003 ATC code A04AD12 (WHO) Route Intravenous therapy | Routes of
administration Intravenous Molar mass 614.406 g/mol | |
 | ||
AHFS/Drugs.com Multum Consumer Information License data EU EMA: Ivemend
US FDA: Fosaprepitant Pregnancy
category US: B (No risk in non-human studies) | ||
Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.
Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 and by the European Medicines Agency (EMA) on January 11 of the same year.
References
Fosaprepitant Wikipedia(Text) CC BY-SA